Latest Ryman Healthcare (NZX:RYM) News

Ryman Healthcare reported steady retirement living sales in Q1 FY27 with a 7% rise in net resales, buoyed by serviced apartments. The company remains on track for FY27 build targets and sees robust aged care occupancy despite housing market headwinds.

Healthcare shares were driven by regulation, capital and commercial deals this week. The biggest moves came from companies that either moved closer to US sales or raised cash to get there.

Ryman Healthcare has launched a NZ$100 million fixed rate bond offer maturing in 2032, aiming to refinance existing debt and diversify its funding sources. The offer includes an exchange mechanism for existing bondholders, with trading in current bonds to be suspended during the transition.

A handful of extreme moves set the tone, from DXN’s explosive AI data centre rerating to steep sell-offs in small-cap explorers. Deals, funding and fresh drilling results drove the week, but several gap-ups lost steam as traders banked profits.

Healthcare stocks split into two camps this week. Buyers chased clear commercial wins, while several halted names gave back early excitement once trading resumed. The biggest moves came from a collapse in Opthea, a surge in Control Bionics, and a strong jump in Biome Australia after a margin-boosting manufacturing deal.

Ryman Healthcare nearly doubles operating profitability and generates positive free cash flow for the first time in over a decade, while shifting strategy toward sustainable growth and targeting dividend returns by FY28.

Speculative small caps drove the week, with Tasman Resources, Solis Minerals and Lithium Energy leading the board after funding, drilling and asset sale updates. At the other end, ASX Ltd and Arafura Rare Earths fell hard as investors reacted to higher costs and fresh equity issuance.

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.

Ryman Healthcare reported a substantial reduction in net loss for FY26 alongside its first positive free cash flow in over a decade, driven by operational improvements, refinancing, and land divestments.

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.

Ryman Healthcare’s FY26 retirement living sales hit 1,410 ORAs, aligning with guidance despite a Q4 dip in new sales. The company reports robust aged care occupancy and expects free cash flow near NZD 180 million.